In the original article, there was an error. We mistakenly stated that 5-MeO-DMT is part of the ayashuasca brew.

A correction has been made to the ***Introduction***, paragraph one:

"Psychoactive tryptamines are a class of molecules that act as a neurotransmitter in the vertebrate brain (Jacob and Presti, [@B10]). N,N-dimethyltryptamine, (DMT) and analogues, are closely related to 5-methoxy- N,N-dimethyltryptamine (5-MeO-DMT), they can be found in a great variety of plants in South America, with an even greater diversity of chemical analogs (Geyer et al., [@B6]; Greene, [@B7]). 5-MeO-DMT is a serotonin agonist that acts in a non-selective manner in 5-HT~2A~ \>5-HT~2C~ \>5-HT~1A~ receptors (Szabo et al., [@B15]). However, the N-N-DMT has been reported elsewhere to also acts in many glutamate, dopamine, and acethylcholine receptors (Carbonaro and Gatch, [@B2]). It would be interesting to know whether the 5-MeO-DMT have the same effect as its analogue on those receptors. The 5-MeO-DMT is analogous of the N,N-DMT, one of the main active ingredients of *Ayahuasca*, a millenarian decoction used as a sacrament by south American indigenous tribes, known to induce powerful hallucinogenic states when administered with monoamine oxidase inhibitors (MAOI; Araújo et al., [@B1]). At present, *Ayahuasca* is used by many syncretic churches ritualistically, as a way to heal many physical and mental illnesses with or without scientific knowledge about the effects (Frecska et al., [@B4]). Recent studies also suggest that *Ayahuasca* can potentially treat recurrent depression (Osório Fde et al., [@B12]; Sanches et al., [@B14]) even in a placebo controlled frame (Palhano-Fontes et al., [@B13])."

Additionally, a correction has been made to the ***Discussion***, paragraph three:

"The choice of a single dose treatment, was made to address the gap between the molecular mechanisms, subjective and hormonal effects underlying *Ayahuasca* acute administration to depression diagnosed patients (dos Santos et al., [@B3]; Sanches et al., [@B14]; Galvão et al., [@B5]; Palhano-Fontes et al., [@B13]). The bulk of *Ayahuasca* tea, are composed of several psychoactive substances including DMT analogs and MAOi (Frecska et al., [@B4]; Morales-García et al., [@B11]). The scope of present study is to unveil the effect of the 5-MeO-DMT, without adding any bias, due to other psychoactive compounds. To study the specific contribution of the 5-MeO-DMT to the adult neurogenic process, we needed to isolate the effect of the 5-MeO-DMT from other psychoactive components. In *Ayahuasca* tea the DMT is administrated with MAOi, in order to avoid tryptamines degradation. Using oral or intraperitoneal administration without MAOi may reduce the availability of 5-MeO-DMT to the central nervous system, since the monoamine oxidase will readily destroy any tryptamine, in the bloodstream, guts and also in the brain (Halberstadt et al., [@B9]; Halberstadt, [@B8]; Morales-García et al., [@B11]). Since 5-MeO-DMT can easily be degraded, we chose to deliver the 5-MeO-DMT i.c.v. to reduce the chemical inactivation prior to the arrival of the molecule to the brain. Additionally, it has been reported elsewhere that the harmine *per se* can increase neurogenesis, at least *in vitro* cultured hippocampal cells (Morales-García et al., [@B11])."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
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